Myris Therapeutics
Myris Therapeutics uses breakthrough advances in Polymer Chemistry to engineer novel next-generation medicines. Our flagship platform of ultra-high DAR antibody drug conjugates changes the conversation around payload choice.
technology
Myris ADCs utilize the ATRP ‘growing from’ technology to build polymer bottlebrushes on which payloads are attached. The polymers convey solubility and ultra-high DAR.
Our ultra-high DAR capability changes the conversation around which payloads can be used. When DAR is limited to DAR 1-8, payloads must be highly toxic, leading to unwanted side effects. With DARs 10-100 fold greater, the payloads can be less cytotoxic yet still very potent in blocking essential molecular pathways that drive cancer. We can also mix payloads to leverage synthetic lethality or target a central molecular pathway and its resistence mechanisms.
PIPELINE
